BREAST CANCER

A 59-Year-Old Woman With HER2+ De Novo Metastatic Breast Cancer

Indigenous American ancestry has been linked to an increased incidence of HER2-positive breast cancer, according to the Peruvian Genetics and Genomics of Breast Cancer Study study published in Cancer Research.

The FDA has accepted and granted a priority review to a supplemental Biologics License Application for pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic solid tumors with tissue tumor mutational burden-high who have progressed following prior treatment and who have no satisfactory alternative treatment options.

Treatment with sacituzumab govitecan resulted in “compelling evidence of efficacy” in patients with metastatic triple-negative breast cancer, leading to an early halt of the phase III ASCENT study, announced Immunomedics in a press release.

Kevin Hughes, MD, discusses how genetic testing has changed and how much testing should be done for patients with breast cancer.

A statistically significant improvement in the total pathologic complete response rate, the primary end point of the study, was observed with neoadjuvant treatment of pertuzumab, trastuzumab and docetaxel compared with placebo, trastuzumab, and docetaxel in Asian patients with&nbsp;<a><em>ERBB2</em></a>&nbsp;-positive early or locally advanced breast cancer, according to the phase III PEONY trial.

A 54-Year-Old Woman With Stage 2 HER2+ Breast Cancer

An association was found between a lower risk of grade 3 or higher chemotherapy toxicity with higher body mass indexes and normal albumin, a protein made in the liver, levels in older adult patients with solid tumors, according to an analysis of a prospective, multicenter study.

A sudden surge in the cases of COVID-19 due to pandemic, along with efforts to contain it, has led to multiple challenges that no country has experienced in the last several decades. The global pandemic from COVID-19 poses a unique set of challenges not only for patients with cancer who need their treatment, but also for caregivers, oncologists, and the overall care team.

Patients with early-stage breast cancer who received pelareorep demonstrated consistent data with safety run-in data and had a favorable toxicity profile, according to an cohort analysis from the window-of-opportunity study, AWARE-1.

The FDA has approved a new 420-mg multi-dose vial of Ontruzant a biosimilar of trastuzumab, according to a press release from Samsung Bioepis.

In an interview with&nbsp;Targeted Oncology, Kashyap Patel, MD, discussed the COVID-19 pandemic and the implementation of new precautions in his practice as the number of COVID-19 infected persons rises in the state.<br /> &nbsp;

Patients harboring IDH1/2 muta&shy;tions may receive benefit by the use of PARP inhibitors, with investigators initi&shy;ating clinical trials in patients across multiple different tumor types to determine the efficacy of this strategy.

Treatment with pembrolizumab demonstrated antitumor activity along with tolerable toxicity in patients with 4 different rare and hard-to-treat malignancies, according to results from a phase II study led by The University of Texas MD Anderson Cancer Center researchers and published in the&nbsp;Journal for ImmunoTherapy of Cancer.